While the arms were mostly well-balanced, Arm A (neoadjuvant) enrolled patients that were likely to be older (p = 0.005), Hispanic or Latino (p = 0.03), had lower PD-L1 tumor cell positivity (p = 0.023), and had numerically more patients with PALN positivity (not statistically significant). Here, CD274 is linked to neoplasm.